NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
26 March 2025
| Name: | BLUECHIIP LIMITED (BCT) |
| ISIN: | AU000000BCT7 |
| Date of Listing: | 09 June 2011 |
Stock Exchange Status: (updated daily)
This entity is currently suspended from quotation on the Australian Securities Exchange and its securities cannot be traded on-market.Legal Status: (updated monthly)
ACN: 104 795 922ABN: 79 104 795 922
Registration Date: 20 May 2003
Capital Gains Tax (CGT) Status: (updated at least quarterly)
The securities in this entity, in our opinion, are of little or no value. We have made that assessment by reference to the circumstances leading to a suspension and/or delisting, the length of a suspension, share trading history and last on-market share price, most recent financial and cash flow statements, prospects (including likelihood of re-financing), and other factors including in particular whether the entity is in external administration. If you are seeking to crystallise a capital loss on your securities, that process can be easily and quickly initiated at our online Worthless Shares facility here: https://www.delisted.com.au/sell-worthless-and-other-securities/.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
Automic Registry Pty Ltd
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail
Expand this box to read and print
The company's securities were suspended from quotation due to breach of Listing Rule 12.2, and will remain suspended until ASX determines compliance and reinstates them to quotation. | 17/03/2025 |
Manuel Hanna of Romanis Cant is appointed Administrator | 17/03/2025 |
Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person. | 07/03/2025 |
The company releases its results of its annual general meeting. | 30/01/2025 |
The company releases a letter to shareholders. Shareholders suspended until 2024 audited accounts and Annual Report lodged. Strategic Review focused on partnerships, re-financing, and investment. BioLife deal announced, sales revenue expected. | 30/01/2025 |
The company releases its Quarterly Activities and Quarterly Appendix 4C Cash Flow Report. | 30/01/2025 |
The entities suspended for over three months failed periodic reports, the oldest outstanding report deadline, and their 2 year deadline for trading plans. If not met, they will be removed from the official list, usually after the first trading day. | 22/01/2025 |
The Annual General Meeting will be held at 11:00am (AEDT) on 30 January 2025 at the Offices of Phillips Ormonde Fitzpatrick, Level 16, 333 Collins Street, Melbourne, VIC 3000. | 30/12/2024 |
The company has announced a strategic review and initiated an interim capital raising. The company has entered a partnership with BioLife Solutions and continues to build direct market sales to 38 labs across 18 customers. The company's annual meeting is set for January 2025. | 20/12/2024 |
The company has signed an exclusive license, development, and supply agreement with BioLife Solutions, a leading provider of bioproduction tools and services for Cell and Gene Therapy. BioLife will integrate Bluechiip's unique technology into its proprietary primary packaging containers, a significant milestone for Bluechiip, with potential for ongoing royalties and product sales. | 02/12/2024 |
The company has been granted an extension by ASIC, allowing it to hold its Annual General Meeting until January 31, 2025, after completing its strategic process. | 26/11/2024 |
The company lodges its Quarterly Activities & Appendix 4C Cash Flow Report. | 31/10/2024 |
The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 1 October 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Monday, 30 September 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 01/10/2024 |
The suspension of trading in the securities of Bluechiip Limited will be lifted immediately, following the release by BCT of an announcement regarding a purported termination of a chip supply agreement with Labcon North America. | 16/07/2020 |
Labcon North America has provided notice to Bluechiip purporting to terminate the chip supply agreement it has with Bluechiip. Bluechiip considers that the termination is unlawful. Labcon has also asserted in its correspondence a claim for damages in the region of US$500,000 which Bluechiip categorically refutes. Negotiations with Labcon have now ceased and as a result Bluechiip has instructed its lawyers to pursue all rights and remedies available to it under the supply agreement, including, but not limited to, recovery from Labcon of an outstanding balance of US$3.5million which Bluechiip considers is now immediately due and payable. | 16/07/2020 |
The securities of Bluechiip Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of BCT, pending the release of an announcement regarding the outcome of the discussions with Labcon. | 14/07/2020 |
The suspension of trading in the securities of Bluechiip Limited (the "Company") will be lifted immediately, following the release of an announcement by the Company today. Security Code: BCT | 20/08/2013 |
The securities of Bluechiip Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement. Security Code: BCT | 16/08/2013 |
The securities of Viralytics Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement in relation to the outcome of a capital raising. Security Code: VLA | 21/11/2012 |
The securities of Bluechiip Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement. Security Code: BCT | 15/11/2012 |
The company's securities were suspended from quotation due to breach of Listing Rule 12.2, and will remain suspended until ASX determines compliance and reinstates them to quotation. | 17/03/2025 |
Manuel Hanna of Romanis Cant is appointed Administrator | 17/03/2025 |
Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person. | 07/03/2025 |
The company releases its results of its annual general meeting. | 30/01/2025 |
The company releases a letter to shareholders. Shareholders suspended until 2024 audited accounts and Annual Report lodged. Strategic Review focused on partnerships, re-financing, and investment. BioLife deal announced, sales revenue expected. | 30/01/2025 |
The company releases its Quarterly Activities and Quarterly Appendix 4C Cash Flow Report. | 30/01/2025 |
The entities suspended for over three months failed periodic reports, the oldest outstanding report deadline, and their 2 year deadline for trading plans. If not met, they will be removed from the official list, usually after the first trading day. | 22/01/2025 |
The Annual General Meeting will be held at 11:00am (AEDT) on 30 January 2025 at the Offices of Phillips Ormonde Fitzpatrick, Level 16, 333 Collins Street, Melbourne, VIC 3000. | 30/12/2024 |
The company has announced a strategic review and initiated an interim capital raising. The company has entered a partnership with BioLife Solutions and continues to build direct market sales to 38 labs across 18 customers. The company's annual meeting is set for January 2025. | 20/12/2024 |
The company has signed an exclusive license, development, and supply agreement with BioLife Solutions, a leading provider of bioproduction tools and services for Cell and Gene Therapy. BioLife will integrate Bluechiip's unique technology into its proprietary primary packaging containers, a significant milestone for Bluechiip, with potential for ongoing royalties and product sales. | 02/12/2024 |
The company has been granted an extension by ASIC, allowing it to hold its Annual General Meeting until January 31, 2025, after completing its strategic process. | 26/11/2024 |
The company lodges its Quarterly Activities & Appendix 4C Cash Flow Report. | 31/10/2024 |
The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 1 October 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Monday, 30 September 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 01/10/2024 |
The suspension of trading in the securities of Bluechiip Limited will be lifted immediately, following the release by BCT of an announcement regarding a purported termination of a chip supply agreement with Labcon North America. | 16/07/2020 |
Labcon North America has provided notice to Bluechiip purporting to terminate the chip supply agreement it has with Bluechiip. Bluechiip considers that the termination is unlawful. Labcon has also asserted in its correspondence a claim for damages in the region of US$500,000 which Bluechiip categorically refutes. Negotiations with Labcon have now ceased and as a result Bluechiip has instructed its lawyers to pursue all rights and remedies available to it under the supply agreement, including, but not limited to, recovery from Labcon of an outstanding balance of US$3.5million which Bluechiip considers is now immediately due and payable. | 16/07/2020 |
The securities of Bluechiip Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of BCT, pending the release of an announcement regarding the outcome of the discussions with Labcon. | 14/07/2020 |
The suspension of trading in the securities of Bluechiip Limited (the "Company") will be lifted immediately, following the release of an announcement by the Company today. Security Code: BCT | 20/08/2013 |
The securities of Bluechiip Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement. Security Code: BCT | 16/08/2013 |
The securities of Viralytics Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement in relation to the outcome of a capital raising. Security Code: VLA | 21/11/2012 |
The securities of Bluechiip Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement. Security Code: BCT | 15/11/2012 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 08/06/2022 | Iain Kirkwood | 750,000 | $0.030 | $22,350 |
| 31/08/2020 | Andrew Cox | 500,000 | $0.772 | $386,000 |
| 06/12/2017 | Iain Kirkwood | 950,000 | $0.044 | $41,850 |
| 17/06/2016 | Andrew McLellan | 110,000 | $0.024 | $2,640 |
| 12/05/2016 | Michael Ohanessian | 136,654 | $0.020 | $2,733 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Iain Kirkwood | Non Exec Chairman, Company Secretary | 01/11/2007 |
| Andrew McLellan | Managing Director | 27/01/2015 |
| Andrew Cox | Non Exec Director | 26/07/2017 |
| Michael Ohanessian | Non Exec Director | 15/12/2014 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Patricia Vanni | Company Secretary | 05/07/2024 | 20/12/2024 |
| Chelsea Sheridan | Company Secretary | 05/07/2024 | |
| Blair Healy | Non Exec Director | 23/08/2017 | 26/11/2018 |
| Matthew Morgan | Non Exec Director | 03/02/2014 | 17/03/2016 |
| Jason Chaffey | Managing Director | 28/01/2014 | 15/12/2014 |
| Joe Baini | Non Exec Director | 06/08/2010 | 01/08/2014 |
| Ron Finkel | Non Exec Director | 02/07/2012 | 01/08/2014 |
| Brett Schwarz | Managing Director | 09/12/2003 | 28/01/2014 |
| Larry Lopez | Non Exec Director | 02/09/2010 | 11/10/2011 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
